LIMES SCHLOSSKLINIK. O.N.

Limes Schlosskliniken reaches a multi-year high, driven by its network of seven premium private clinics specializing in mental, stress-related and psychosomatic disorders. The business model deliberately targets wealthy self-paying patients and recipients of civil-servant benefits, which supports the stock’s strength in the small-cap segment. The share stands out in an otherwise lethargic German stock market. » More on finanzen.net

GMF Capital GmbH reported insider transactions: on 30 June 2026, 3,000 Limes Schlosskliniken shares were sold at EUR 540.00 each (execution 2 July 2026). Earlier, the executive had already disposed of 3,000 shares at EUR 530.00 each on 11 June 2026. The stock last traded around EUR 535.00; market capitalization approx. EUR 165 million with 300,000 tradable shares. » More on finanzen.net

The supervisory board of LIMES Schlosskliniken has approved the 2025 annual and consolidated financial statements and recommends that the annual general meeting approve a dividend of €10.00 per share. The published consolidated figures correspond to the preliminary results; the final 2025 business figures will be announced on 11 May 2026. The 2026 financial year has started stronger than planned: in the first quarter total performance was €15.5 million (+38% year-on-year) and EBITDA was €3.9 million (+32%). » More on de.investing.com